Enovis (NYSE:ENOV) Trading Up 4.6% – What’s Next?

Enovis Corporation (NYSE:ENOV) shot up 4.6% during mid-day trading on Tuesday . The stock traded as high as $25.78 and last traded at $25.87. Approximately 60,484 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 1,100,257 shares. The stock had previously closed at $24.74.

Analysts Set New Price Targets

Several research firms have recently weighed in on ENOV. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Canaccord Genuity Group reduced their target price on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday. Wells Fargo & Company decreased their price target on Enovis from $40.00 to $39.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. UBS Group restated a “buy” rating and set a $51.00 price objective (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Finally, Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and an average target price of $41.29.

Enovis Price Performance

The company has a market cap of $1.53 billion, a PE ratio of -1.38 and a beta of 1.34. The stock has a fifty day moving average price of $25.04 and a 200-day moving average price of $24.11. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. The business had revenue of $582.78 million for the quarter, compared to the consensus estimate of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.Enovis’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts expect that Enovis Corporation will post 3.15 earnings per share for the current year.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert purchased 1,200 shares of Enovis stock in a transaction dated Thursday, June 11th. The stock was acquired at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the transaction, the insider directly owned 51,840 shares of the company’s stock, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders bought 4,200 shares of company stock valued at $92,084. 2.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ENOV. Private Management Group Inc. boosted its stake in shares of Enovis by 38.8% during the 2nd quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock valued at $28,257,000 after buying an additional 381,705 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of Enovis in the second quarter worth $48,000. Corient Private Wealth LP purchased a new stake in shares of Enovis during the second quarter worth $338,000. Bank of America Corp DE purchased a new stake in shares of Enovis during the second quarter worth $11,502,000. Finally, Man Group plc acquired a new stake in Enovis during the second quarter valued at $8,711,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.